Evidence map›Paper›PMID 40804412›Full record

ReviewDiagnostic pathology2025

Uterine leiomyoma-like inflammatory myofibroblastic tumour with a rare ALK::SYN3 fusion: a clinicopathologic and molecular analysis.

Cao Ma, Xiaoying Wei, Zhe Chen, Xiangzhi Hao, Yuping Sun, Jie Zi, Chunyan Chu, Lihua Zhang

Abstract readCase ReportsReview
In one paragraph

Review in Diagnostic pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cao MaDepartment of Pathology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China.
Xiaoying WeiDepartment of Pathology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China.
Zhe ChenDepartment of Pathology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China.
Xiangzhi HaoDepartment of Pathology, Lai'an County People's Hospital, Chuzhou, China.
Yuping SunDepartment of Pathology, Lai'an County People's Hospital, Chuzhou, China.
Jie ZiDepartment of Pathology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China.
Chunyan ChuDepartment of Pathology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China.
Lihua ZhangDepartment of Pathology, School of Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China. 15905179393@126.com.

Funding

National Natural Science Foundation of China 82300784Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High-Level Hospital Construction Funds 2024GSPKY32
6 · The paper itself

Abstract

Uterine inflammatory myofibroblastic tumour (IMT) is a relatively rare mesenchymal tumour of the uterus, with recurrence and metastasis rates of 25% and 2%, respectively. As IMT frequently harbours ALK gene rearrangements, some patients may benefit from treatment with tyrosine kinase inhibitors, making accurate identification of this tumour essential. Here, we report the case of a 38-year-old female patient with a tumour clinically resembling uterine leiomyoma. Microscopically, the spindled tumour cells were arranged in orderly intersecting fascicles, accompanied by a sparse infiltrate of inflammatory cells and a notable absence of myxoid matrix. Immunohistochemistry and molecular testing revealed an ALK::SYN3 fusion, suggesting the diagnosis of a uterine leiomyoma-like inflammatory myofibroblastic tumour (UL-like IMT). UL-like IMT is exceedingly rare and can easily be misdiagnosed as smooth-muscle tumours based solely on clinical manifestations and morphology. Therefore, it is recommended that the diagnosis be based on a combination of histopathological features, immunohistochemical markers, and genetic testing results to ensure a comprehensive and accurate assessment.

Indexed as

Anaplastic Lymphoma KinaseBiomarkers, TumorLeiomyomaNeoplasms, Muscle TissueUterine NeoplasmsAdultDiagnosis, DifferentialFemaleGene FusionHumansImmunohistochemistryALK protein, humanAnaplastic Lymphoma KinaseBiomarkers, TumorALKInflammatory myofibroblastic tumourLeiomyomaSYN3Uterine

Identifiers

PMID40804412
PMCPMC12351933

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.